RT Journal Article
SR Electronic
T1 Prognostic Significance of Neoadjuvant Rectal Score and Indication for Postoperative Adjuvant Therapy in Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 283
OP 289
DO 10.21873/invivo.11772
VO 34
IS 1
A1 MAEDA, KIYOSHI
A1 SHIBUTANI, MASATSUNE
A1 TACHIMORI, AKIKO
A1 NISHII, TAKAFUMI
A1 AOMATSU, NAOKI
A1 FUKUOKA, TATSUNARI
A1 NAGAHARA, HISASHI
A1 OTANI, HIROSHI
A1 INOUE, TORU
A1 OHIRA, MASAICHI
YR 2020
UL http://iv.iiarjournals.org/content/34/1/283.abstract
AB Background/Aim: Neoadjuvant chemoradiotherapy (CRT) is a standard treatment for patients with clinical Stage II/III rectal cancer. However, the benefit of postoperative adjuvant chemotherapy for patients after neoadjuvant CRT is uncertain. Recently, neoadjuvant rectal (NAR) score was suggested as an independent prognostic factor for patients with rectal cancer after neoadjuvant CRT. The aim of this study was to examine the prognostic significance of NAR score in rectal cancer patients who underwent neoadjuvant CRT followed by surgery, and to investigate which patients may benefit from postoperative adjuvant therapy. Patients and Methods: A total of 72 patients who underwent neoadjuvant CRT followed by R0 resection for clinical stage II /III rectal cancer were evaluated. The correlation between NAR score, various clinicopathological factors and disease recurrence were evaluated. Results: Disease recurrence was significantly more often observed in patients with incomplete neoadjuvant CRT, tumor regression grade (TRG) 3-4, and high NAR score. Multivariate analysis revealed that NAR score was an independent predictor of disease recurrence. Conclusion: NAR score may be one of the predictive markers for disease recurrence in patients who underwent neoadjuvant CRT followed by surgery for rectal cancer. Patients with a low NAR score may benefit form postoperative adjuvant chemotherapy.